EA202092251A1 - Комбинированные продукты для лечения rsv - Google Patents

Комбинированные продукты для лечения rsv

Info

Publication number
EA202092251A1
EA202092251A1 EA202092251A EA202092251A EA202092251A1 EA 202092251 A1 EA202092251 A1 EA 202092251A1 EA 202092251 A EA202092251 A EA 202092251A EA 202092251 A EA202092251 A EA 202092251A EA 202092251 A1 EA202092251 A1 EA 202092251A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
methyl
compound
imidazo
pyridin
Prior art date
Application number
EA202092251A
Other languages
English (en)
Inventor
Нина Исебарт
Неле Иса Э. Гуйвартс
Дирк Андре Э. Ройманс
Анил Коул
Original Assignee
Янссен Сайенсиз Айрлэнд Юси
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Сайенсиз Айрлэнд Юси filed Critical Янссен Сайенсиз Айрлэнд Юси
Publication of EA202092251A1 publication Critical patent/EA202092251A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение направлено на комбинацию ингибирующего RSV соединения A, т.е. 3-({5-хлор-1-[3-(метилсульфонил)пропил]-1H-индол-2-ил}метил)-1-(2,2,2-трифторэтил)-1,3-дигидро-2H-имидазо[4,5-c]пиридин-2-она, и одного или нескольких ингибирующих RSV соединений B, выбранных из рибавирина, GS-5806, MDT-637, BTA-9881, BMS-433771, YM-543403, A-60444, TMC-353121, RFI-641, CL-387626, MBX-300, AZ-27, MEDI8897, CR9501, паливизумаба, 3-({5-хлор-1-[3-(метилсульфонил)пропил]-1H-бензимидазол-2-ил}метил)-1-циклопропил-1,3-дигидро-2H-имидазо[4,5-c]пиридин-2-она, 3-[[7-хлор-3-(2-этилсульфонилэтил)имидазо[1,2-a]пиридин-2-ил]метил]-1-циклопропилимидазо[4,5-c]пиридин-2-она, N-(2-фтор-6-метилфенил)-6-(4-(5-метил-2-(7-окса-2-азаспиро[3.5]нонан-2-ил)никотинамидо)бензоил)-5,6-дигидро-4H-бензо[b]тиено[2,3-d]азепин-2-карбоксамида и 4-амино-8-[3-[[2-(3,4-диметоксифенил)этил]амино]пропил]-6,6-диметил-2-(4-метил-3-нитрофенил)-3H-имидазо[4,5-h]изохинолин-7,9-(6H,8H)-диона, предназначенную для лечения или уменьшения интенсивности RSV-инфекции. Настоящее изобретение дополнительно относится к комбинированному продукту на основе соединения A и одного или нескольких соединений B, к фармацевтическому продукту, содержащему соединение A и одно или несколько соединений B, к применению комбинации соединения A и одного или нескольких соединений B или фармацевтического продукта, содержащего соединение A и одно или несколько соединений B, для лечения RSV-инфекции и к способу лечения или уменьшения интенсивности RSV-инфекции у субъекта, нуждающегося в этом, предусматривающему введение комбинации соединения А и одного или нескольких соединений B в эффективном количестве указанному субъекту.
EA202092251A 2016-02-03 2017-02-02 Комбинированные продукты для лечения rsv EA202092251A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16154035 2016-02-03

Publications (1)

Publication Number Publication Date
EA202092251A1 true EA202092251A1 (ru) 2020-12-11

Family

ID=55304886

Family Applications (3)

Application Number Title Priority Date Filing Date
EA202092250A EA202092250A1 (ru) 2016-02-03 2017-02-02 Комбинированные продукты для лечения rsv
EA201891655A EA037206B1 (ru) 2016-02-03 2017-02-02 Комбинация для лечения и ослабления rsv инфекции и фармацевтическая композиция на её основе
EA202092251A EA202092251A1 (ru) 2016-02-03 2017-02-02 Комбинированные продукты для лечения rsv

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EA202092250A EA202092250A1 (ru) 2016-02-03 2017-02-02 Комбинированные продукты для лечения rsv
EA201891655A EA037206B1 (ru) 2016-02-03 2017-02-02 Комбинация для лечения и ослабления rsv инфекции и фармацевтическая композиция на её основе

Country Status (19)

Country Link
US (1) US10363253B2 (ru)
EP (2) EP3411028B1 (ru)
JP (1) JP7065030B2 (ru)
KR (1) KR20180108598A (ru)
CN (2) CN112245429A (ru)
AU (2) AU2017214246B2 (ru)
BR (1) BR112018014958A2 (ru)
CA (1) CA3006488A1 (ru)
CL (3) CL2018001808A1 (ru)
EA (3) EA202092250A1 (ru)
ES (1) ES2877808T3 (ru)
IL (2) IL259669B (ru)
MX (2) MX381654B (ru)
MY (1) MY197217A (ru)
PH (2) PH12020551598B1 (ru)
SG (1) SG11201806581TA (ru)
UA (1) UA124099C2 (ru)
WO (1) WO2017134133A1 (ru)
ZA (1) ZA201805205B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017531039A (ja) 2014-10-10 2017-10-19 プルモシデ リミテド 新規５，６−ジヒドロ−４Ｈ−ベンゾ［ｂ］チエノ−［２，３−ｄ］アゼピン誘導体
JP6694886B2 (ja) 2014-12-18 2020-05-20 プルモシデ リミテド ４，５−ジヒドロ−６Ｈ−チエノ［３，２−ｄ］ベンゾアゼピン誘導体及び呼吸器合胞体ウイルス（ＲＳＶ）感染を治療するためのその使用
WO2017175000A1 (en) 2016-04-08 2017-10-12 Pulmocide Limited Compounds
TW201936193A (zh) * 2017-12-05 2019-09-16 愛爾蘭商健生科學愛爾蘭無限公司 使用組合產品治療ｒｓｖ
AU2020372633A1 (en) * 2019-10-30 2022-04-21 Janssen Sciences Ireland Unlimited Company Synthesis of 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2 yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one
CN114014856B (zh) * 2021-11-26 2023-12-22 嘉兴安谛康生物科技有限公司 作为呼吸道合胞病毒抗病毒剂的咪唑并吡啶类衍生物
CN116077494A (zh) * 2023-01-11 2023-05-09 黑龙江中医药大学 一种治疗呼吸道合胞病毒的药物组合物及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI515187B (zh) 2010-12-16 2016-01-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之吲哚類
KR102236497B1 (ko) * 2013-04-25 2021-04-06 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 가용성 예비융합 ｒｓｖ ｆ 폴리펩타이드
AU2014308991B2 (en) 2013-08-21 2019-02-14 Janssen Biopharma, Inc. Antiviral compounds
JP2017531039A (ja) * 2014-10-10 2017-10-19 プルモシデ リミテド 新規５，６−ジヒドロ−４Ｈ−ベンゾ［ｂ］チエノ−［２，３−ｄ］アゼピン誘導体

Also Published As

Publication number Publication date
IL259669B (en) 2021-03-25
BR112018014958A2 (pt) 2019-01-08
AU2017214246A1 (en) 2018-06-21
IL277281A (en) 2020-10-29
CA3006488A1 (en) 2017-08-10
MX2020012592A (es) 2022-10-27
WO2017134133A1 (en) 2017-08-10
CL2019001455A1 (es) 2019-08-16
UA124099C2 (uk) 2021-07-21
MX2018009422A (es) 2018-12-19
SG11201806581TA (en) 2018-09-27
IL277281B (en) 2021-04-29
EA202092250A1 (ru) 2020-12-11
MY197217A (en) 2023-06-01
AU2017214246B2 (en) 2022-03-31
MX381654B (es) 2025-03-13
IL259669A (en) 2018-07-31
AU2022202070A1 (en) 2022-04-14
EP3892273A2 (en) 2021-10-13
JP2019504102A (ja) 2019-02-14
ES2877808T3 (es) 2021-11-17
EP3892273A3 (en) 2021-12-22
PH12018501649A1 (en) 2019-06-03
CL2018001808A1 (es) 2018-08-31
EP3411028A1 (en) 2018-12-12
EA037206B1 (ru) 2021-02-19
CN108601774A (zh) 2018-09-28
EA201891655A1 (ru) 2018-12-28
CL2019001454A1 (es) 2019-08-16
KR20180108598A (ko) 2018-10-04
US20190054084A1 (en) 2019-02-21
ZA201805205B (en) 2020-10-28
PH12020551598A1 (en) 2021-05-10
CN108601774B (zh) 2021-09-21
PH12018501649B1 (en) 2021-10-13
PH12020551598B1 (en) 2024-05-17
US10363253B2 (en) 2019-07-30
JP7065030B2 (ja) 2022-05-11
CN112245429A (zh) 2021-01-22
EP3411028B1 (en) 2021-05-05

Similar Documents

Publication Publication Date Title
EA202092251A1 (ru) Комбинированные продукты для лечения rsv
CY1125460T1 (el) Ενωσεις ιμιδαζο [4,5-d]πυρρολο [2,3-β]πυριδινης ως αναστολεις κινασων janus
JP2019504102A5 (ru)
RU2007146390A (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
MA39162A1 (fr) Composés nicotinamide substitués par un hétéroaryle
EA201270498A1 (ru) 8-этил-6-(арил)пиридо[2,3-d]пиримидин-7(8h)-оны для лечения заболеваний цнс
HUE064667T2 (hu) Pirido[3',4':4,5]pirrolo[1,2,3-de]kinoxalin származékok központi idegrendszeri betegségek kezelésében történõ alkalmazásra
FI3805222T3 (fi) 7-bentsyyli-4-(2-metyylibentsyyli)-2,4,6,7,8,9-heksahydroimidatso[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-onijohdannaisia, niiden suoloja ja niiden käyttö hoidossa
EA200600064A1 (ru) Производные тиенопиридона как ингибиторы киназ
RU2015148189A (ru) ПРОИЗВОДНЫЕ 2-АМИДОПИРИДО[4, 3-d]ПИРИМИДИН-5-ОНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ WEE-1
PE20150723A1 (es) Compuestos antiviricos para el vsr
EA201591932A1 (ru) ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНОВ ДЛЯ ЛЕЧЕНИЯ ЛИМФОМ
MX392531B (es) Formas morficas de g1t38 y metodos de preparacion de las mismas.
EA201991109A1 (ru) ПРОИЗВОДНЫЕ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2
PE20090944A1 (es) PIRIMIDINAS BICICLICAS FUSIONADAS COMO INHIBIDORES DE LA VIA Pi3K/AKT
ATE486602T1 (de) Pyrrolo (3, 2, 1-ij) chinolin-4-on-derivate zur behandlung von tuberkulose
HRP20190808T1 (hr) Spiro-indolini za liječenje i profilaksu infekcije respiratornim sincicijskim virusom (rsv)
RU2019108259A (ru) Комбинированная терапия для лечения гепатоцеллюлярной карциномы
AR106647A1 (es) Compuesto piranodipiridínico
EA202091363A1 (ru) Лечение rsv комбинированным продуктом
MX383514B (es) Pirrolo[2,3-d]piridazin-4-onas sustituidas y pirazolo[3,4-d]piridazin-4-onas como inhibidores de la proteína quinasa.
RU2022104462A (ru) Фармацевтические соединения
MX2016002581A (es) Formulaciones farmaceuticas novedosas que comprenden un inhibidor de pde5.
AR094932A1 (es) Formas sólidas de derivados heterocíclicos bicíclicos
PH12018501490A1 (en) Use of inhibitors of the activity or function of pi3k for the treatment of primary sj™gren's syndrome